ANI Pharma (ANIP) Tops Q3 EPS by 43c

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.27, $0.43 better than the analyst estimate of $0.84. Revenue for the quarter came in at $131.83 million versus the consensus estimate of $111.92 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim